Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1439-1447

  Mindrescu, Catalin ^a,b   Gupta, Rakesh P ^a   Hermance, Eileen V ^a   DeVoe, Mary C ^a   Soma, Vikas R ^a   Coppola, John T ^a,b   Staniloae, Cezar S ^a,b  

^a ST VINCENT S HOSPITAL MANHATTAN   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Dyslipidemia; Endothelial function; Omega 3 fatty acids; Rosuvastatin; South Asians

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DOSE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SOUTH ASIA; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; AGED; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FATTY ACIDS, OMEGA-3; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; NEW YORK; PYRIMIDINES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 60249089128     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Barua RS, Ambrose JA, Eales-Reynolds LJ, et al. 2002. Heavy and light cigarette smokers have similar dysfunction of endothelial vasoregulatory activity: an in vivo and in vitro correlation. J Am Coll Cardiol, 39:1758-63.
2. Bedi US, Singh S, Syed A, et al. 2006. Coronary artery disease in South Asians: an emerging risk group. Cardiol Rev, 14:74-80.
3. Bjerregaard P and Dyerberg J. 1988. Fish oil and ischaemic heart disease in Greenland. Lancet, 2:514.
4. Bonetti PO, Lerman LO, Lerman A, et al. 2003. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol, 23:168-75.
5. Calder PC. 2004. n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond), 107:1-11.
6. Corretti MC, Anderson TJ, Benjamin EJ, et al. 2002. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol, 39:257-65.
7. Das UN. 2000. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essent Fatty Acids, 63:351-62.
8. Das UN. 2001. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids, 65:37-40.
9. Dimmeler S, Fleming I, Fisslthaler B, et al. 1999. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 399:601-5.
10. Donald AE, Halcox JP, Charakida M, et al. 2008. Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation. J Am Coll Cardiol, 51:1959-64.
11. Dupuis J, Tardif JC, Cernacek P, et al. 1999. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation, 99:3227-33.
12. Engler MB, Engler MM, Ursell PC, et al. 1994. Vasorelaxant properties of n-3 polyunsaturated fatty acids in aortas from spontaneously hypertensive and normotensive rats. J Cardiovasc Risk, 1:75-80.
13. Engler MM, Engler MB, Malloy M, et al. 2004. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. Int J Clin Pharmacol Ther, 42:672-9.
14. Faulx MD, Wright AT, Hoit BD, et al. 2003. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J, 145:943-51.
15. Flachs P, Mohamed-Ali V, Horakova O, et al. 2006 Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia, 2006;49:394-7.
16. Fulton D, Gratton JP, McCabe TJ, et al. 1999. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 399:597-601.
17. Galley HF and Webster NR.2004. Physiology of the endothelium. Br J Anaesih, 93:105-13.
18. [GISS] Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet, 354:447-55.
19. Goode GK, Garcia S, Heagerty AM, et al. 1997. Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. Circulation, 96:2802-7.
20. Gupta M, Singh N, Verma S, et al. 2006. South Asians and cardiovascular risk: what clinicians should know. Circulation, 113:e924-9.
21. Hernandez-Perera O, Pérez-Sala D, Navarro-Antolín J, et al. 1998. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest, 101:2711-19.
22. Laufs U, La Fata V, Plutzky J, et al. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 97:1129-35.
23. Leung WH, Lau CP, Wong CK, et al. 1993 Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet, 341:1496-500.
24. Liao JK and Laufs U. 2005. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol, 45:89-118.
25. McVeigh GE, Brennan GM, Johnston GD, et al. 1993. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 36:33-8.
26. Mori TA, Watts GF, Burke V, et al. 2000. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation, 102:1264-9.
27. [NCEP] Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). 2001. JAMA, 285:2486-97.
28. Newman WP, Middaugh JP, Propst MT, et al. 1993. Atherosclerosis in Alaska Natives and non-natives. Lancet, 341:1056-7.
29. Omoni H, Nagashima H, Tsurumi Y, et al. 2002. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol, 54:395-9.
30. Sheu WH, Juang BL, Chen YT, et al. 1999. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care, 22:1224-5.
31. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. 1995. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J, 74:247-53.
32. Staniloae C, Mandadi V, Kurian D, et al. 2006.Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology, 108:164-9.
33. Tagawa H, Shimokawa H, Tagawa T, et al. 1999. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol, 33:633-40.
34. ter Avest E, Abbink EJ, Holewijn S, et al. 2005. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Curr Med Res Opin, 21:1469-76.
35. Treasure CB, Klein JL, Weintraub WS, et al. 1995. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med, 332:481-7.
36. Van de Ree MA, Huisman MV, de Man FH, et al. 2001. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res, 52:299-305.
37. van Etten RW, de Koning EJ, Honing ML, et al. 2002. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol, 22:799-804.
38. Vane JR, Anggard EE, Botting RM, et al. 1990. Regulatory functions of the vascular endothelium. N Engl J Med, 323:27-36.
39. Yusuf S, Hawken S, Ounpuu S, et al. 2004. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364:937-52.